Masters Speciality Pharma

    Founded over 30 years ago, Masters Speciality Pharma is an international pharmaceutical company specialising in the distribution of unlicensed medicinal products to Physicians, Hospitals, Clinics, Government institutions and individual patients, providing access to essential life-saving treatments worldwide.

Masters is fully compliant with regulatory requirements in all jurisdictions enabling us to deliver tailored medical solutions to over 90 countries worldwide, and is trusted as a reliable source of pharmaceutical product
Company Type
Company Sub-Type

Medherant Limited

Medherant is a leading developer of next-generation transdermal drug delivery patches.

Transdermal delivery of drugs from a patch provides better control of the dose than achieved with gels, ointments and creams.  However, the currently available technologies limit the types of drugs that can be used and the quantities that can be loaded into the patch.  Medherant’s TEPI Patch® is formulated with a novel polymer adhesive that is mixed with the drug.

One of the key advantages of the TEPI Patch® technology is that a greater quantity of drug can be blended with the adhesive.  This enables lower potency drugs to be formulated as a patch and provides the opportunity to increase the dose of drugs already administered via a patch.  The TEPI Patch® also provides a better experience for the user as it does not leave a residue around the patch – referred to as ‘cold flow’ – and has excellent adhesion whilst still being easy and painless to remove.

Medherant is developing its own TEPI Patch® products and working with third parties to assess the suitability of the technology for their drugs.  

The Company expects to earn revenues from licensing both its products and its technology for use with specific drugs.

Company Type
Company Sub-Type
Twitter Account
@medherant

MediWales

MediWales is the life science network and representative body for Wales.
An independent, not-for-profit organisation that is owned by its members, MediWales provides advice, support, business opportunities and promotes collaborations for the life science and health technology community in Wales.

MediWales delivers an extensive events programme, including the UK HealthTech conference and the MediWales Innovation Awards and produces a number of publications including UK Lifescience Industry magazine, the Annual Directory and Review, and case study magazine LifeStories. MediWales promotes and supports its members in Wales, across the UK and internationally. 

Company Type
Company Sub-Type
Twitter Account
@mediwales

MGB Biopharma Ltd

MGB Biopharma is a private company based in Glasgow, Scotland and is backed by a syndicate of Scotland’s leading angel investor groups together with Scottish Enterprise. Antimicrobial drug resistance is recognised as a global public health concern with an urgent need for new antibacterial drug classes that are more effective than existing treatments. MGB is developing the first truly novel class of anti-infectives in over a decade that has the potential to treat infections of a number of the most important susceptible and resistant pathogens.

Our lead compound has shown strong bactericidal activity with quick onset of action against many strains of Gram-positive bacteria. It has completed pre-clinical development and progress into our phase 1 clinical study for the treatment of Clostridium difficile have been endorsed by the MHRA. Optimisation of a new formulation for intravenous administration and treatment of systemic Gram-positive infection is ongoing.

MGB has acquired exclusive rights to the proprietary minor groove binder platform, developed at the University of Strathclyde, Glasgow. This platform provides an opportunity to develop additional compounds with the potential to treat Gram-negative, viral, fungal and parasitic infections. MGB continues to work closely with Strathclyde University to develop the pipeline and is currently seeking partners to help maximise the value-creating opportunities from its broad platform.

Company Type
Company Sub-Type
Twitter Account
@MGB_Biopharma

Mironid

Mironid Limited is an innovative new drug discovery company that develops proprietary drug candidate molecules by modulating the activity of key cell signalling proteins. This allows us to access multiple therapeutic areas for exploitation. Our current drug discovery pipeline is aimed at developing novel treatments for degenerative kidney diseases, chronic inflammatory diseases and cancer.

Company Type
Twitter Account
@mironidltd